Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer

Key facts

Sponsor

Aronex Pharmaceuticals

Principal Investigator

David S. Gordon, MD

Aronex Pharmaceuticals

Intervention

amphotericin B deoxycholate(drug)

Eligibility

2 years · All sexes

Timeline

1996 – 2007

Study locations (30)

• Veterans Affairs Medical Center - Phoenix (Hayden), Phoenix, Arizona, United States
• Holt-Krock Clinic, Fort Smith, Arkansas, United States
• Arkansas Children's Hospital, Little Rock, Arkansas, United States
• Office of Rosalda Rodriguez, M.D., Chula Vista, California, United States
• Beckman Research Institute, City of Hope, Duarte, California, United States
• Eisenhower Medical Center, Rancho Mirage, California, United States
• University of Colorado Cancer Center, Denver, Colorado, United States
• New Britain General Hospital, New Britain, Connecticut, United States
• Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington D.C., District of Columbia, United States
• Sylvester Cancer Center, University of Miami, Miami, Florida, United States
• Tampa Children's Hospital, Tampa, Florida, United States
• Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
• St. John's Pavilion - Springfield Clinic Research Department, Springfield, Illinois, United States
• University of Kansas Medical Center, Kansas City, Kansas, United States
• Lake Charles Medical and Surgical Clinic, Lake Charles, Louisiana, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT06303193
  Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
  National Cancer Institute (NCI)
• RECRUITINGPHASE3NCT07422480
  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
  Takeda
• RECRUITINGNANCT07500753
  A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly Patients
  The First Affiliated Hospital of Soochow University
• RECRUITINGPHASE4NCT07486713
  Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
  Rigel Pharmaceuticals
• RECRUITINGPHASE1NCT07107126
  Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
  Remedy Plan, Inc.
• RECRUITINGPHASE1NCT07270978
  Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
  University of Virginia
• RECRUITINGNANCT06781099
  Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis
  Hospices Civils de Lyon
• RECRUITINGPHASE2NCT07228273
  Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
  OHSU Knight Cancer Institute

See all trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent →